Canadian Journal of Cardiology最新文献

Endocarditis prophylaxis - indications, application and current controversies. 心内膜炎的预防-指征，应用和目前的争议。

IF 5.3 2区医学

Canadian Journal of Cardiology Pub Date : 2025-10-14 DOI: 10.1016/j.cjca.2025.10.011

Martin H Thornhill, Mark J Dayer, Bernard D Prendergast, Larry M Baddour

{"title":"Endocarditis prophylaxis - indications, application and current controversies.","authors":"Martin H Thornhill, Mark J Dayer, Bernard D Prendergast, Larry M Baddour","doi":"10.1016/j.cjca.2025.10.011","DOIUrl":"https://doi.org/10.1016/j.cjca.2025.10.011","url":null,"abstract":"Links between infective endocarditis (IE) and dental and other invasive procedures were first identified in the 1920s, leading to the first recommendation by the American Heart Association (AHA) in 1955 that antibiotic prophylaxis (AP) should be used to prevent IE. Recognising the weak evidence to support this practice and the wider risks of anaphylaxis and antibiotic resistance, guidelines in the USA and Europe have been rationalised in the last two decades, restricting the use of AP to the highest risk patients (and the complete cessation of AP for all invasive procedures in the UK). However, recent data demonstrate that AP is safe and effective in reducing the incidence of IE in high-risk individuals undergoing invasive dental procedures and support current European Society of Cardiology (ESC) and AHA guidance,. Nonetheless, debate continues, and several questions remain. Which patients should receive AP? Which dental and non-dental procedures require AP? And which AP regimens and other preventive measures are safest and most cost-effective? In this narrative review, we address these controversies with reference to recent literature and clinical experience.","PeriodicalId":9555,"journal":{"name":"Canadian Journal of Cardiology","volume":" ","pages":""},"PeriodicalIF":5.3,"publicationDate":"2025-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145306842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pericardial Delivery of Stem Cells: An Emerging Frontier in Myocardial Regeneration for Ischemic Heart Disease. 心包干细胞输送：缺血性心脏病心肌再生的新前沿。

IF 5.3 2区医学

Canadian Journal of Cardiology Pub Date : 2025-10-14 DOI: 10.1016/j.cjca.2025.10.012

Aliya Izumi, Terrence M Yau, Paul W M Fedak, Ali Fatehi Hassanabad

{"title":"Pericardial Delivery of Stem Cells: An Emerging Frontier in Myocardial Regeneration for Ischemic Heart Disease.","authors":"Aliya Izumi, Terrence M Yau, Paul W M Fedak, Ali Fatehi Hassanabad","doi":"10.1016/j.cjca.2025.10.012","DOIUrl":"https://doi.org/10.1016/j.cjca.2025.10.012","url":null,"abstract":"Cardiac regenerative therapies have seen limited clinical translation due to persistent challenges in stem cell viability, retention, and demonstration of efficacy. The pericardial space, however, has emerged as a dynamic reservoir of bioactive substances capable of modulating cellular processes within the myocardium. Pericardial delivery of stem cells offers a promising solution to modern translational roadblocks by leveraging the pericardial space for its proximity to the heart, protective compartmentalization, and favorable biochemical milieu. Preclinical studies using cardiospheres, cardiosphere-derived cells, and mesenchymal stem cells have demonstrated significant improvements in cardiac function, infarct size reduction, and vascular regeneration after myocardial infarction. Additionally, epicardial hydrogels and percutaneous pericardial injections have been shown to reduce local immune responses and enable broader therapeutic distribution compared with intramyocardial and intracoronary approaches. As a potential cardiac surgical adjuvant therapy, pericardial delivery of stem cells represents an exciting frontier in cardiac regeneration, warranting further research to define its role in clinical practice.","PeriodicalId":9555,"journal":{"name":"Canadian Journal of Cardiology","volume":" ","pages":""},"PeriodicalIF":5.3,"publicationDate":"2025-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145306894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Quality of Life in Adults with Transposition of the Great Arteries: Lessons Beyond Survival. 成人大动脉转位的生活质量：生存之外的教训。

IF 5.3 2区医学

Canadian Journal of Cardiology Pub Date : 2025-10-14 DOI: 10.1016/j.cjca.2025.10.008

Waleed Alhumaid, Isabelle Vonder Muhll

引用次数: 0

Does Lightning Strike the Same Place Twice : Recurrent Stroke Post-Bentall with Tissel embolism. 雷击同一个地方两次：本垒打后复发性中风伴Tissel栓塞。

IF 5.3 2区医学

Canadian Journal of Cardiology Pub Date : 2025-10-13 DOI: 10.1016/j.cjca.2025.10.007

Bedirhan Bugra Bayici, Fatih Kizilyel

引用次数: 0

Heart in the Crossfire: Immune Checkpoint Inhibitor Mediated Cardiotoxicity. 战火中的心脏：免疫检查点抑制剂介导的心脏毒性。

IF 5.3 2区医学

Canadian Journal of Cardiology Pub Date : 2025-10-11 DOI: 10.1016/j.cjca.2025.10.006

Vineet Goyal, Arjun A Raghavan, Davinder S Jassal

引用次数: 0

Current State of Drug Therapies for Antibody Mediated Rejection After Heart Transplantation. 心脏移植后抗体介导排斥反应的药物治疗现状。

IF 5.3 2区医学

Canadian Journal of Cardiology Pub Date : 2025-10-10 DOI: 10.1016/j.cjca.2025.10.005

Erik Henricksen, Krysta Walter, Alicia Lichvar

{"title":"Current State of Drug Therapies for Antibody Mediated Rejection After Heart Transplantation.","authors":"Erik Henricksen, Krysta Walter, Alicia Lichvar","doi":"10.1016/j.cjca.2025.10.005","DOIUrl":"https://doi.org/10.1016/j.cjca.2025.10.005","url":null,"abstract":"Antibody mediated rejection (AMR) continues to be a significant and challenging complications following heart transplantation (OHT), contributing significantly to morbidity and mortality. Despite its clear clinical impact, there is no clear consensus on optimal treatment strategies due to a paucity of prospective clinical trials and the immunological nuances of this rejection phenotype. Therapeutic plasma exchange and intravenous immune globulin remain the cornerstones of a majority of AMR protocols. However, there is growing evidence of the use of additional therapies that target more specific antibody mechanisms. Anti-CD20 antibodies, proteasome inhibitors, anti-CD38 antibodies, IL-6 receptor antagonists, and complement inhibitors have been used to reverse AMR and mitigate its deleterious consequences. However, these medications come with their own nuances and considerations for use. Therefore, the purpose of this review article will be to provide practical \"how-to\" information on the utilizations of these agents, including prescribing, dosing strategies, monitoring approaches, and duration of treatment. Additionally, a key focus will be placed on adverse effects profiles associated with AMR treatment with these novel agents through monitoring and risk mitigation approaches to ensure patient safety. In this way, this review aims to serve as a comprehensive and practical guide for clinicians, synthesizing existing data on both standard and emerging AMR therapies to improve patient outcomes following heart transplantation.","PeriodicalId":9555,"journal":{"name":"Canadian Journal of Cardiology","volume":" ","pages":""},"PeriodicalIF":5.3,"publicationDate":"2025-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145279012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Enhancing Valve Selection and Outcome Assessment in Transcatheter Aortic Valve Replacement After Surgical Mitral Replacement: Next-Step Strategies. 加强二尖瓣置换术后经导管主动脉瓣置换术的瓣膜选择和结果评估：下一步策略。

IF 5.3 2区医学

Canadian Journal of Cardiology Pub Date : 2025-10-09 DOI: 10.1016/j.cjca.2025.10.004

Weikai Dong, Zhengdong Lu

引用次数: 0

Right ventricular systolic and diastolic parameters based on pressure-volume loop theory in heart failure. 基于压力-容量循环理论的心衰右心室收缩和舒张参数。

IF 5.3 2区医学

Canadian Journal of Cardiology Pub Date : 2025-10-09 DOI: 10.1016/j.cjca.2025.09.048

Yoshitaka Isotani, Eisuke Amiya, Masaru Hatano, Junichi Ishida, Masaki Tsuji, Chie Bujo, Shun Minatsuki, Takahiro Kurihara, Satoshi Ishii, Hiroki Yagi, Akihito Saito, Hiroyuki Kiriyama, Genri Numata, Saki Kaneko, Satoru Ando, Kei Morishita, Norifumi Takeda, Issei Komuro, Norihiko Takeda

{"title":"Right ventricular systolic and diastolic parameters based on pressure-volume loop theory in heart failure.","authors":"Yoshitaka Isotani, Eisuke Amiya, Masaru Hatano, Junichi Ishida, Masaki Tsuji, Chie Bujo, Shun Minatsuki, Takahiro Kurihara, Satoshi Ishii, Hiroki Yagi, Akihito Saito, Hiroyuki Kiriyama, Genri Numata, Saki Kaneko, Satoru Ando, Kei Morishita, Norifumi Takeda, Issei Komuro, Norihiko Takeda","doi":"10.1016/j.cjca.2025.09.048","DOIUrl":"https://doi.org/10.1016/j.cjca.2025.09.048","url":null,"abstract":"Background: This study aimed to assess the clinical utility of right ventricular (RV) systolic and diastolic parameters derived from the RV pressure waveform obtained through right heart catheterization (RHC) based on pressure-volume (PV) loop theory in patients with heart failure (HF).Methods: The study included patients hospitalized for advanced HF who underwent RHC at our institution. RV end-systolic elastance (Ees), RV arterial elastance (Ea), RVEes/Ea ratio and RV diastolic stiffness coefficient (β) were calculated from RV pressure waveforms. The prognostic value of these parameters was evaluated for the primary outcome defined as all-cause mortality or urgent HF-related hospitalization.Results: A total of 254 patients were analyzed, including 141 with a left ventricular ejection fraction (LVEF) <40% and 113 with LVEF ≥40%. Among the RV systolic and diastolic parameters, a low RVEes/Ea ratio (<0.55) (hazard ratio [HR], 4.1; 95% confidence interval [CI], 2.4-6.9; p < 0.001) and an elevated RVβ (≥0.025) (HR, 4.8; 95% CI, 2.5-9.0; p < 0.001) were associated with a higher risk of the primary outcome. In those with LVEF <40%, a low RVEes/Ea ratio was a stronger independent predictor of the primary outcome (HR, 3.5; 95%CI, 1.6-7.5; p = 0.002), whereas in those with LVEF ≥40%, elevated RVβ was the more significant independent risk factor (HR, 3.0; 95%CI, 1.1-8.2; p = 0.029), even after multiple adjustments for covariate factors.Conclusion: RV waveform evaluation based on PV loop theory was effective in predicting prognosis in HF patients, irrespective of LVEF.","PeriodicalId":9555,"journal":{"name":"Canadian Journal of Cardiology","volume":" ","pages":""},"PeriodicalIF":5.3,"publicationDate":"2025-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145273855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Aortic Root Enlargement in the Era of Transcatheter Valve Intervention. 经导管瓣膜介入时代主动脉根部扩张的研究。

IF 5.3 2区医学

Canadian Journal of Cardiology Pub Date : 2025-10-08 DOI: 10.1016/j.cjca.2025.09.045

Quynh Nguyen, Daniel R Wong

引用次数: 0

Blood Flow Dynamics of Self-Expanding versus Balloon-Expandable Transcatheter Aortic Valve Replacement in Patients with a Small Aortic Annulus. 小主动脉环患者自我扩张与球囊扩张经导管主动脉瓣置换术的血流动力学。

IF 5.3 2区医学

Canadian Journal of Cardiology Pub Date : 2025-10-07 DOI: 10.1016/j.cjca.2025.09.046

Takeshi Hamaya, Kiwamu Kamiya, Toshiyuki Nagai, Satonori Tsuneta, Noriko Oyama-Manabe, Hirokazu Komoriyama, Yuki Takahashi, Akinori Takahashi, Yuki Mori, Yoshifumi Mizuguchi, Sakae Takenaka, Suguru Ishizaka, Takuma Sato, Taro Temma, Yasushige Shingu, Kohsuke Kudo, Satoru Wakasa, Toshihisa Anzai

{"title":"Blood Flow Dynamics of Self-Expanding versus Balloon-Expandable Transcatheter Aortic Valve Replacement in Patients with a Small Aortic Annulus.","authors":"Takeshi Hamaya, Kiwamu Kamiya, Toshiyuki Nagai, Satonori Tsuneta, Noriko Oyama-Manabe, Hirokazu Komoriyama, Yuki Takahashi, Akinori Takahashi, Yuki Mori, Yoshifumi Mizuguchi, Sakae Takenaka, Suguru Ishizaka, Takuma Sato, Taro Temma, Yasushige Shingu, Kohsuke Kudo, Satoru Wakasa, Toshihisa Anzai","doi":"10.1016/j.cjca.2025.09.046","DOIUrl":"https://doi.org/10.1016/j.cjca.2025.09.046","url":null,"abstract":"Background: A recent trial showed the supra-annular self-expanding valve (SEV) provides superior valve function compared to the balloon-expandable valve (BEV) in patients with aortic stenosis (AS) and a small aortic annulus (SAA) undergoing transcatheter aortic valve replacement (TAVR). This study aimed to compare blood flow hemodynamics between SEV and BEV using four-dimensional flow cardiovascular magnetic resonance imaging (4D flow CMR).Methods: We prospectively examined 166 consecutive patients with AS who underwent TAVR between May 2018 and March 2025. SAA was defined as an annular area ≤ 430 mm2. Patients were categorized into four groups: SAA-SEV (n = 35), SAA-BEV (n = 66), non-SAA-SEV (n = 21), and non-SAA-BEV (n = 44). Blood flow patterns, wall shear stress (WSS), and energy loss were assessed using 4D flow CMR.Results: In patients with SAA, the SEV group showed significantly greater absolute reductions in vortical flow, helical flow, and flow eccentricity after TAVR compared to the BEV group (-0.47 ± 0.9 vs. 0.15 ± 1.0, P = 0.003; -0.79 ± 0.8 vs. -0.36 ± 0.9, P = 0.008; and -0.59 ± 0.9 vs. -0.20 ± 0.8, P = 0.024, respectively). The absolute reduction of average WSS was also significantly greater in the SEV group (-2.0 [-3.0 to -0.9] Pa vs. -0.9 [-2.5 to 0.4] Pa, P = 0.037). These differences were not observed in the non-SAA groups.Conclusions: In SAA patients undergoing TAVR, SEV demonstrated a significantly greater reduction in abnormal blood flow patterns and average WSS than BEV.","PeriodicalId":9555,"journal":{"name":"Canadian Journal of Cardiology","volume":" ","pages":""},"PeriodicalIF":5.3,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145257477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0